-
7 Things The US Could Do With Apple's Strategically Avoided Taxes
Tuesday, November 7, 2017 - 5:09pm | 740Read More...Through “stateless” subsidiaries and shadow companies, Apple Inc. (NASDAQ: AAPL) amassed $252 billion in offshore cash subject to foreign tax rates far lower than the U.S.’s 35 percent, according to BBC News. In 2017 alone, the firm made $44.7 billion outside the U.S. and...
-
What Would A $5.8 Billion NIH Cut Look Like? Devastation
Thursday, April 20, 2017 - 1:38pm | 1882Read More...Neither Republicans nor Democrats are eager to cut the National Institutes of Health funding by the president’s suggested $5.8 billion, but with the proposal still on the table, the sum is not yet safe. And as 18 percent of the current $31.7 billion budget hangs in the balance, more Americans...
-
What Passage Of The 21st Century Cures Act Means For Biotech Stocks
Thursday, December 8, 2016 - 12:41pm | 479Read More...Congressional Republicans and Democrats joined forces on Thursday to pass the 21st Century Cures Act, a comprehensive piece of healthcare legislation that provides funding for researching some of America’s biggest health concerns. Senate Vote 94–5 The legislation passed a Senate vote 94...
-
Heat Biologics CEO Interview Abuzz With Zika Developments: Collaboration, Vaccine And Other Initiatives
Monday, October 31, 2016 - 1:54pm | 529Read More...Last Tuesday, Heat Biologics Inc (NASDAQ: HTBX) announced its collaboration with the University of Miami to research a Zika virus vaccine. The research will implement the existing gp96 platform. Essentially, gp96 is a molecule present in all human cells, which interacts with proteins to trigger an...
-
HC Wainwright Bullish On Proteon Therapeutics, Sees 105% Potential Upside
Thursday, September 22, 2016 - 11:15am | 375Read More...HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...
-
Sony and Illumina Set to Change the Way Doctors Identify and Treat Cancer (ILMN, SNE)
Thursday, September 5, 2013 - 2:55pm | 519Read More...In a story first reported by Nikkei and updated recently by Le Monde, Sony Corp. (NYSE: SNE) and U.S. genome sequencing equipment maker Illumina Inc. (NASDAQ: ILMN) plan to launch a human genome analysis project in October. The project will involve the study and analysis of genetic material...







